OptiNose (NASDAQ:OPTN) issued its earnings results on Thursday. The company reported ($0.70) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.01, MarketWatch Earnings reports. The firm had revenue of $4.48 million during the quarter, compared to the consensus estimate of $4.35 million. OptiNose had a negative return on equity of 73.97% and a negative net margin of 983.22%.
NASDAQ OPTN traded up $0.33 during trading on Friday, hitting $9.58. 172,236 shares of the company’s stock were exchanged, compared to its average volume of 135,278. The company has a current ratio of 8.28, a quick ratio of 8.01 and a debt-to-equity ratio of 0.61. The company has a market cap of $381.70 million, a price-to-earnings ratio of -3.57 and a beta of 0.78. OptiNose has a fifty-two week low of $5.66 and a fifty-two week high of $30.00.
Several research analysts have commented on the company. Cantor Fitzgerald reissued a “buy” rating and set a $27.00 target price on shares of OptiNose in a research note on Thursday. Piper Jaffray Companies set a $29.00 target price on OptiNose and gave the stock a “buy” rating in a research note on Tuesday, April 23rd. Royal Bank of Canada lowered their target price on OptiNose to $25.00 and set an “outperform” rating for the company in a research note on Thursday, March 7th. Finally, Zacks Investment Research downgraded OptiNose from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. OptiNose presently has an average rating of “Buy” and a consensus price target of $27.80.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/11/optinose-optn-announces-quarterly-earnings-results.html.
OptiNose Company Profile
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Further Reading: What strategies should day traders use to execute a trade?
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.